A

Akero Therapeutics
D

AKRO

50.535
USD
0.04
(0.07%)
مغلق
حجم التداول
35,377
الربح لكل سهم
-4
العائد الربحي
-
P/E
-13
حجم السوق
4,028,527,400
أصول ذات صلة
SUSHIUSD
SUSHIUSD
0.01518
(1.67%)
0.92500 USD
AAVEUSD
AAVEUSD
3.10
(1.05%)
299.14 USD
C
COMP
0.09000
(1.26%)
7.22500 USD
S
SNX
1.010
(0.69%)
146.930 USD
المزيد
الأخبار المقالات

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.